IDEXX Laboratories, Inc. $IDXX Shares Sold by Kestra Advisory Services LLC

Kestra Advisory Services LLC lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 50.3% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 3,631 shares of the company’s stock after selling 3,674 shares during the quarter. Kestra Advisory Services LLC’s holdings in IDEXX Laboratories were worth $1,896,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. J.Safra Asset Management Corp bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth about $25,000. Elevation Wealth Partners LLC raised its holdings in IDEXX Laboratories by 188.2% in the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock valued at $26,000 after acquiring an additional 32 shares during the period. Pension & Wealth Management Advisors Inc. bought a new position in IDEXX Laboratories in the 3rd quarter valued at about $29,000. Arlington Trust Co LLC raised its holdings in IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after acquiring an additional 19 shares during the period. Finally, Bell Investment Advisors Inc lifted its position in IDEXX Laboratories by 45.5% during the third quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after acquiring an additional 20 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Michael Lane sold 3,979 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $688.64, for a total transaction of $2,740,098.56. Following the transaction, the executive vice president owned 4,076 shares in the company, valued at $2,806,896.64. This represents a 49.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lawrence D. Kingsley sold 2,203 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 41,428 shares of company stock worth $28,567,934. Company insiders own 0.79% of the company’s stock.

IDEXX Laboratories Trading Down 1.5%

Shares of IDEXX Laboratories stock opened at $690.24 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.88 and a current ratio of 1.19. The firm has a 50-day moving average of $569.11 and a 200-day moving average of $573.65. IDEXX Laboratories, Inc. has a 52-week low of $500.61 and a 52-week high of $769.98. The stock has a market cap of $54.38 billion, a PE ratio of 47.34 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a net margin of 25.36% and a return on equity of 71.04%. The business had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period last year, the firm earned $3.22 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 9.9% compared to the same quarter last year. As a group, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. BTIG Research dropped coverage on shares of IDEXX Laboratories in a research report on Friday, October 30th. They set a “buy” rating for the company. UBS Group upped their target price on IDEXX Laboratories from $627.00 to $700.00 and gave the company a “neutral” rating in a research report on Tuesday, November 3rd. JPMorgan Chase & Co. lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research note on Friday, October 16th. Morgan Stanley increased their target price on IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. Finally, Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

View Our Latest Stock Report on IDXX

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Further Reading

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.